EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
1245.110: A phase III randomized, double-blind placebo controlled trial to evaluate efficacy and safety of once daily empagliflozin 10 mg in patients with heart failure with preserved ejection fraction.
The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction (HFpEF >40%).
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.